Hims & Hers Health (NYSE:HIMS – Get Free Report) had its price objective increased by equities research analysts at Canaccord Genuity Group from $28.00 to $38.00 in a report released on ...

Dr. Lokesh, Associate Professor in the Department of General Medicine in the Hassan Institute of Medical Sciences, was ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) shares were up 6.6% during trading on Tuesday after Canaccord Genuity Group raised their price target on the stock from $28.00 to $38.00.

Eleven cases of hypertrichosis — commonly known as “werewolf syndrome” — has developed in babies throughout Spain.

Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, is proud to announce its ...

The American Diabetes Association is advising doctors and patients not to use compounded GLP-1s due to uncertainty about their content, safety, ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

This penchant for calls isn't entirely unusual, given the stock's 50-day call/put volume ratio of 3.55 at the International ...

Zscaler (ZS) stock is brushing off strong fiscal first-quarter results after also issuing a disappointing forecast ...

Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.

The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...

Canaccord raised the firm’s price target on Hims & Hers to $38 from $28 and keeps a Buy rating on the shares. The stock rallied 70% in ...